Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abeona Therapeutics Inc. (ABEO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, and its filings offer detailed insight into the business, including the commercialization of ZEVASKYN® (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) and the development of AAV-based gene therapies for ophthalmic conditions.
Investors can review current reports on Form 8-K, where Abeona reports material events such as quarterly financial results, operational updates on ZEVASKYN manufacturing and launch activities, and transactions like the sale of a Rare Pediatric Disease Priority Review Voucher awarded upon FDA approval of ZEVASKYN. These filings also confirm that Abeona’s common stock, with a par value of $0.01 per share, trades on The Nasdaq Capital Market under the symbol ABEO.
In addition to 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for information on Abeona’s research and development spending, selling, general and administrative expenses related to the ZEVASKYN launch, cash and investment balances, debt obligations, and risk factor disclosures relevant to its gene therapy programs and manufacturing operations.
Stock Titan enhances these documents with AI-powered summaries that help explain key sections of lengthy filings, such as revenue descriptions, cost structures, and updates on regulatory interactions. The platform also surfaces insider transaction reports on Form 4 when filed, enabling users to track equity awards and other changes in beneficial ownership by Abeona’s officers and directors.
By combining real-time EDGAR updates with AI-generated highlights, this ABEO filings page is designed to make Abeona’s complex biopharmaceutical and gene therapy disclosures more accessible to investors, analysts, and other interested readers.
Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 29,985 shares of common stock in an open-market transaction. The sale occurred on March 31, 2026 at a weighted average price of $4.3849 per share, with individual trades between $4.31 and $4.43.
After the transaction, Seshadri directly held 1,430,423 shares of Abeona common stock. The filing states that the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2024, indicating it was scheduled in advance.
ABEO filed a Form 144 notifying a proposed sale of 29,985 shares of Common Stock. The filing identifies these shares as Restricted Stock dated 06/05/2024 and notes a prior sale of 69,832 shares on 01/22/2026 for $372,267.00.
The notice lists the broker Stifel Nicolaus & Company Inc and indicates Nasdaq as the exchange; timing and proceeds distribution beyond the amounts shown are not detailed in the excerpt.
Abeona Therapeutics Inc. ownership filing reports that Daniel Kaufman beneficially owns 2,943,629 shares of Common Stock, representing 5.16% of the class. The filing lists Kaufman’s sole voting and dispositive power over these shares.
The Schedule 13G is signed by Daniel Kaufman on 03/27/2026 and discloses his address and CUSIP 00289Y206.
Abeona Therapeutics Inc ownership update: The Vanguard Group filed an amendment reporting zero shares beneficially owned of Abeona common stock following an internal realignment. The filing states Vanguard's subsidiaries will report separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own the securities reported by those subsidiaries.
Abeona Therapeutics Inc. reported that its Board approved Third Amended and Restated Bylaws, effective March 16, 2026, fully replacing bylaws adopted in July 2024. The revisions clarify how annual and special shareholder meetings can be called, postponed, rescheduled, or canceled, and expressly allow virtual meetings under Delaware law.
The bylaws eliminate the requirement to make a shareholder list available at meetings, add rules for attending meetings via remote communication, and raise the quorum requirement from one-third to 50% of shares entitled to vote. They also strengthen procedural and disclosure requirements for shareholder proposals and director nominations, including conditions for using the SEC’s universal proxy rules.
Abeona Therapeutics Inc. is now a commercial-stage cell and gene therapy company following U.S. FDA approval of ZEVASKYN® on April 28, 2025 for treating wounds in adults and children with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disease with no cure.
ZEVASKYN® is the first and only FDA-approved autologous cell-based gene therapy for RDEB wounds and is manufactured at Abeona’s cGMP facility in Cleveland, Ohio. As of March 2026, four qualified U.S. treatment centers are activated, and the company has broad commercial and Medicaid coverage plus a permanent J‑code effective January 1, 2026.
The company sold a Rare Pediatric Disease Priority Review Voucher for $155.0 million, strengthening its cash position, and estimates about 750 moderate-to-severe RDEB patients in the U.S. could be eligible for ZEVASKYN®. Abeona is also advancing AAV-based gene therapies for XLRS (ABO‑503), Stargardt disease (ABO‑504), and ADOA (ABO‑505) using its AIM™ capsid platform and has multiple out‑licensing and capsid-licensing deals supporting additional milestone and royalty potential.
Abeona Therapeutics reported its first full year of commercialization in 2025 with a sharp move to profitability driven by a one-time asset sale. Total revenue was $5.8 million, including $2.4 million in net product revenue from ZEVASKYN and $3.4 million in license and other revenues.
The company recorded a loss from operations of $89.4 million as it ramped commercial infrastructure, but net income reached $71.2 million, or $1.34 per basic share, mainly due to a $152.4 million gain from selling a Priority Review Voucher for $155.0 million. Cash, cash equivalents and short-term investments were $191.4 million as of December 31, 2025. ZEVASKYN, approved by the FDA in April 2025, saw its first commercial treatment in December, with additional biopsies and treatments underway in early 2026.
ABEO reported a Form 144 notice of proposed sales of Common Stock. The filing lists 2,000 Restricted Stock Units tied to equity compensation with a 03/15/2026 date and names Stifel Nicolaus & Company Inc. as broker. It also records a prior sale of 18,666 Common Stock by Joseph Vazzano on 01/22/2026.
Abeona Therapeutics Inc.’s Chief Financial Officer Joseph Walter Vazzano reported an open-market sale of 785 shares of common stock. The shares were sold at $4.76 each on the transaction date to cover tax obligations associated with the vesting of restricted stock awards. After this transaction, he directly holds 567,775 shares of Abeona common stock.
Abeona Therapeutics Inc. filed a report sharing a business update on the commercial launch of its FDA-approved gene therapy ZEVASKYN for recessive dystrophic epidermolysis bullosa (RDEB). Launch activities began in late 2025, with the first patient treated in December before a scheduled facility shutdown.
Manufacturing resumed in late January 2026, with multiple biopsies collected, one additional patient treatment completed, and further biopsies scheduled this quarter. Access is expanding, with coverage policies published by major commercial payers representing about 80 percent of commercially insured lives, full Medicaid coverage, and a permanent CMS HCPCS J-code J3389 effective January 1, 2026.